News
RCKT
26.91
-1.25%
-0.34
Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report?
NASDAQ · 22h ago
Rocket Pharmaceuticals Shakes Up Executive Team, Taps Aaron Ondrey as Finance Chief
Rocket Pharmaceuticals names Aaron Ondrey as chief financial officer. The company says it is shifting its business model toward a commercial-stage gene therapy company. Rocket Pharmaceuticals also appoints Kinnari Patel as president and Jonathan Schwartz as chief medical and gene therapy officer. Rocket is a biopharmaceutical company.
Dow Jones · 1d ago
Rocket Pharmaceuticals Names Aaron Ondrey CFO
NASDAQ · 1d ago
Rocket Pharmaceuticals appoints Aaron Ondrey as CFO
Seeking Alpha · 1d ago
*Rocket Pharmaceuticals Announces Appointment Of Aaron Ondrey As Chief Financial Officer And Additional Updates To Corporate Leadership Team >RCKT
Dow Jones · 1d ago
Weekly Report: what happened at RCKT last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at RCKT last week (0311-0315)?
Weekly Report · 03/18 11:04
Regenxbio: DMD Program Lends Additional Credibility To NAV Technology Platform
RegenXBIO Inc. (NASDAQ:RGNX) has made remarkable progress in advancing its pipeline of gene therapies. The company has reported positive interim results from a study using RGX-202 for the treatment of patients with Duchenne Muscular Dystrophy. It is also on track to file a BLA for its MPS II program in 2024. The odds of the company reaching the finish line have been upgraded from buy to strong buy. Its NAV Technology Platform is building upon next-generation AAV vectors to enhance efficacy.
Seeking Alpha · 03/11 15:53
Weekly Report: what happened at RCKT last week (0304-0308)?
Weekly Report · 03/11 11:01
Weekly Report: what happened at RCKT last week (0226-0301)?
Weekly Report · 03/04 11:03
Rocket Pharmaceuticals' Promising Path In Gene Therapy
Rocket Pharmaceuticals, Inc. Stock surged 76% post a "Buy" recommendation for RP-A501 in Danon disease. The gene therapy is targeting a rare disease without current treatments and promises significant market potential. The company's stock is up 76% since my recommendation in August. If approved, the company should qualify for a rare pediatric disease voucher.
Seeking Alpha · 03/01 23:03
DXCM, CDW and VRM are among after hour movers
On the Move DXCM, CDW and VRM are among after hour movers. Energem (ENCP) and CalAmp (CAMP) are among the Gainers. Sana Biotechnology (SANA) and Vroom (VRM) are the losers.
Seeking Alpha · 03/01 22:42
Rocket Pharmaceuticals Price Target Cut to $54.00/Share From $56.00 by UBS
Dow Jones · 03/01 17:03
Rocket Pharmaceuticals Is Maintained at Buy by UBS
Dow Jones · 03/01 17:03
UBS Maintains Buy on Rocket Pharmaceuticals, Lowers Price Target to $54
Benzinga · 03/01 16:53
Robust Financials and Pipeline Progress Secure Buy Rating for Rocket Pharmaceuticals
TipRanks · 02/28 04:39
Buy Rating Affirmed for Rocket Pharmaceuticals Amid Promising Pipeline and Upcoming Commercial Launch
TipRanks · 02/27 21:55
Rocket Pharmaceuticals Is Maintained at Overweight by JP Morgan
Dow Jones · 02/27 18:35
Rocket Pharmaceuticals Price Target Cut to $50.00/Share From $55.00 by JP Morgan
Dow Jones · 02/27 18:35
JP Morgan Maintains Overweight on Rocket Pharmaceuticals, Lowers Price Target to $50
Benzinga · 02/27 18:25
More
Webull provides a variety of real-time RCKT stock news. You can receive the latest news about Rocket Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About RCKT
Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company. The Company is advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Its lentiviral (LV) vector-based gene therapies target hematologic diseases and consist of late-stage programs for Fanconi Anemia, a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia. It also has two clinical stages and one pre-clinical stage in vivo adeno-associated virus (AAV) programs, including programs for Danon disease, Plakophilin-2 Arrhythmogenic Cardiomyopathy and BAG3 Dilated Cardiomyopathy.